Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Nieforth

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Pharmacokinetics of enfuvirtide in a patient with impaired renal functionClifford Leen, Cynthia Wat, Keith Nieforth
Clinical Pharmacokinetics|January 20, 2005
Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtideIndravadan H Patel, Xiaoping Zhang, Keith Nieforth, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2018
A Regression Approach to Visual Predictive Checks for Population Pharmacometric ModelsKris M Jamsen, Kashyap Patel, Keith Nieforth, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 16, 2026
Multi-objective optimization in population pharmacokinetic model selection and optimization: application of NSGA-II in pyDarwinXinnong Li, Mark Sale, James Craig, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2025
Pirana and Integrated PMX Tools, a Workbench for NONMEM, NLME, pyDarwin, and RsNLMERong Chen, Mark Sale, James Craig, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patientsDiane R Mould, Xiaoping Zhang, Keith Nieforth, et al.
Travel Medicine and Infectious Disease|December 3, 2014
Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellersStephen Toovey, Keith Nieforth, Patrick Smith, et al.
Pediatric Transplantation|May 10, 2008
Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipientsMark D Pescovitz, Stuart Knechtle, Steven R Alexander, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 22, 2025
ADPO: automatic-differentiation-assisted parametric optimizationRong Chen, Mark Sale, Alex Mazur, et al.
Clinical Transplantation|February 6, 2004
Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantationMark D Pescovitz, Ginny Bumgardner, Robert S Gaston, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2004
Pharmacokinetics of enfuvirtide in a patient with impaired renal functionClifford Leen, Cynthia Wat, Keith Nieforth
Clinical Pharmacokinetics|January 20, 2005
Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtideIndravadan H Patel, Xiaoping Zhang, Keith Nieforth, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2018
A Regression Approach to Visual Predictive Checks for Population Pharmacometric ModelsKris M Jamsen, Kashyap Patel, Keith Nieforth, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 16, 2026
Multi-objective optimization in population pharmacokinetic model selection and optimization: application of NSGA-II in pyDarwinXinnong Li, Mark Sale, James Craig, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2025
Pirana and Integrated PMX Tools, a Workbench for NONMEM, NLME, pyDarwin, and RsNLMERong Chen, Mark Sale, James Craig, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patientsDiane R Mould, Xiaoping Zhang, Keith Nieforth, et al.
Travel Medicine and Infectious Disease|December 3, 2014
Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellersStephen Toovey, Keith Nieforth, Patrick Smith, et al.
Pediatric Transplantation|May 10, 2008
Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipientsMark D Pescovitz, Stuart Knechtle, Steven R Alexander, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 22, 2025
ADPO: automatic-differentiation-assisted parametric optimizationRong Chen, Mark Sale, Alex Mazur, et al.
Clinical Transplantation|February 6, 2004
Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantationMark D Pescovitz, Ginny Bumgardner, Robert S Gaston, et al.
Pageof 2